ALSO READWockhardt gets USFDA nod for generic eye drops Wockhardt gets shareholders' nod for raising Rs 1,000 cr via QIP route Wockhardt settles with Teva and its affiliate in London High Court Wockhardt seeks shareholders' nod to raise up to Rs 1,000 crore Wockhardt looks for greener pastures as US FDA issues linger
Drug firm Wockhardt on Monday reported a consolidated net loss of Rs 3.33 crore for the quarter ended September 30, 2017. The company had posted a net profit of Rs 17.02 crore for the corresponding period of previous fiscal, Wockhardt said in a filing to BSE. Total income of the company stood at Rs 1,076.83 crore for the quarter under review.
It was Rs 1,083.33 crore for the same period a year ago. In a separate filing, Wockhardt said its board has appointed Zahabiya Khorakiwala as additional director of the company. Shares of Wockhardt were on Monday trading at Rs 646.35 per scrip on BSE, down 2.44 per cent from its previous close.